BioGend Therapeutics Co., Ltd. (6733) AI Stock Analysis

BioGend Therapeutics Co., Ltd.

(TPEx:6733)

Select Model

Rating:53Neutral

Price Target:TWD 21.50▲(2.38% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong balance sheet and revenue growth are the primary positive factors, but negative cash flows, bearish technical signals, and unfavorable valuation metrics due to losses limit the score.

Positive Factors

Revenue GrowthSustained revenue expansion from 2020 through 2025 indicates growing commercial activity and improving adoption of the company’s products or services. Continued top-line progress can broaden the operating base, support development investment, and improve the path toward eventual profitability.

Negative Factors

Persistent Operating LossesLarge operating and net losses show that the current business model has not yet reached a sustainable earnings base. Even with improvement from prior years, continued losses can constrain internal reinvestment, delay self-funding, and keep profitability dependent on further revenue growth or cost reductions.

BioGend Therapeutics Co., Ltd. (6733) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 2.77B
Dividend Yield: ―
Average Volume (3M): 72.58K
Price to Earnings (P/E): -31.7
Beta (1Y): 0.40
Revenue Growth: 10.74%
EPS Growth: 21.61%
Country: TW
Employees: 34
Sector: General
Sector Strength: 55
Industry: Biotechnology

BioGend Therapeutics Co., Ltd. Business Overview & Revenue Model

Company Description

This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an auto...

BioGend Therapeutics Co., Ltd. Financial Statement Overview

Summary

Rapid revenue growth to 222 million with narrowing net losses and strong gross margins above 70%, combined with an exceptionally strong balance sheet featuring minimal debt, provide a stable foundation despite ongoing unprofitability and negative cash flows.

Income Statement

65Positive

Balance Sheet

90Very Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	236.58M	222.34M	167.65M	109.91M	31.45M	9.27M
Gross Profit	130.16M	160.16M	130.51M	89.62M	22.78M	3.06M
EBITDA	-54.31M	-60.73M	-74.38M	-113.94M	-160.62M	-104.71M
Net Income	-70.37M	-84.61M	-116.47M	-156.32M	-184.46M	-138.49M
Balance Sheet
Total Assets	1.13B	815.38M	912.70M	1.05B	821.82M	1.02B
Cash, Cash Equivalents and Short-Term Investments	849.79M	517.90M	619.02M	724.27M	493.40M	689.28M
Total Debt	4.76M	6.58M	9.43M	13.09M	15.77M	4.42M
Total Liabilities	45.70M	57.74M	66.19M	93.71M	90.56M	80.42M
Stockholders Equity	1.07B	742.09M	817.67M	940.96M	702.86M	887.54M
Cash Flow
Free Cash Flow	-50.16M	-65.52M	-99.56M	-164.76M	-186.96M	-137.47M
Operating Cash Flow	-47.23M	-63.66M	-98.91M	-138.72M	-168.78M	-136.80M
Investing Cash Flow	-384.28M	66.43M	-8.20M	-89.64M	201.70M	-134.27M
Financing Cash Flow	356.28M	-3.70M	-3.64M	396.42M	-4.81M	287.85M

BioGend Therapeutics Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6733 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6733	53Neutral	TWD 2.80B	-31.69	―	―	10.74%	21.61%
TW:6461	42Neutral	TWD 2.94B	-5.62	―	―	-57.87%	-21.67%
TW:6657	38Underperform	TWD 2.69B	-8.88	―	―	-4.36%	1.97%

* General Sector Average

Performance Comparison

TW:6733 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6733	BioGend Therapeutics Co., Ltd.	21.00	-18.18	-46.40%
TW:6461	Intech Biopharm Ltd	26.20	1.30	5.24%
TW:6657	Energenesis Biomedical Co., Ltd.	30.00	-11.10	-27.01%
TW:6926	Shine-On Biomedical Co., Ltd.	60.00	-11.30	-15.85%
TW:6955	Bonraybio Co. Ltd.	87.30	-46.58	-34.79%
TW:7427	Great Novel Therapeutics Biotech & Medicals Corp.	59.00	20.91	54.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

BioGend Therapeutics Co., Ltd. AI Stock Analysis